Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Will OCGN stock go up? - AInvest

Will OCGN stock go up? - AInvest

Click here to get full coverage on Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? - Yahoo Finance

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?  Yahoo Finance

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? - Yahoo Finance

Click here to get full coverage on Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha

Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN)  Seeking Alpha

Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha

Click here to get full coverage on Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan

Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties  Stock Titan

Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan

Click here to get full coverage on OCGN ALERT– Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Ocugen, Inc. (NASDAQ: OCGN) For Potential Securities Violations and Breach of Fiduciary Duty - ACCESS Newswire

OCGN ALERT– Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Ocugen, Inc. (NASDAQ: OCGN) For Potential Securities Violations and Breach of Fiduciary Duty  ACCESS Newswire

OCGN ALERT– Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Ocugen, Inc. (NASDAQ: OCGN) For Potential Securities Violations and Breach of Fiduciary Duty - ACCESS Newswire

Click here to get full coverage on Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial  Benzinga

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga

Click here to get full coverage on Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease - Ocugen

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease  Ocugen

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease - Ocugen

Click here to get full coverage on Ocugen (OCGN) stock forecast: Awaiting regulatory approval – Photo: Shutterstock - Capital.com

Ocugen (OCGN) stock forecast: Awaiting regulatory approval – Photo: Shutterstock  Capital.com

Ocugen (OCGN) stock forecast: Awaiting regulatory approval – Photo: Shutterstock - Capital.com

Click here to get full coverage on OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com

OCGN stock touches 52-week low at $0.52 amid market challenges  Investing.com

OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com

Click here to get full coverage on Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases - GlobeNewswire

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases  GlobeNewswire

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases - GlobeNewswire

Click here to get full coverage on Ocugen Announces Merger with Carisma Therapeutics - TipRanks

Ocugen Announces Merger with Carisma Therapeutics  TipRanks

Ocugen Announces Merger with Carisma Therapeutics - TipRanks

Click here to get full coverage on OCGN Stock: Can New Leadership Save This Biotech Company? - Nasdaq

OCGN Stock: Can New Leadership Save This Biotech Company?  Nasdaq

OCGN Stock: Can New Leadership Save This Biotech Company? - Nasdaq

Click here to get full coverage on Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo Finance

Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ...  Yahoo Finance

Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo Finance

Click here to get full coverage on Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha

Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN)  Seeking Alpha

Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha

Click here to get full coverage on Ocugen to Present at the 2025 Cell & Gene Meeting on the Med - Ocugen

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med  Ocugen

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med - Ocugen

Click here to get full coverage on Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan

Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal  Stock Titan

Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan

Click here to get full coverage on Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

Ocugen stock gains on licensing deal (OCGN:NASDAQ)  Seeking Alpha

Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

Click here to get full coverage on Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Breakthrough: FDA Green-Lights Ocugen's Gene Therapy Trial After 48% Disease Slowdown in Phase 1 - Stock Titan

Breakthrough: FDA Green-Lights Ocugen's Gene Therapy Trial After 48% Disease Slowdown in Phase 1  Stock Titan

Breakthrough: FDA Green-Lights Ocugen's Gene Therapy Trial After 48% Disease Slowdown in Phase 1 - Stock Titan

Click here to get full coverage on Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges  Yahoo Finance

Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Click here to get full coverage on Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa - Yahoo Finance

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa  Yahoo Finance

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa - Yahoo Finance

Click here to get full coverage on FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood Blindness - No Current Treatment Exists - Stock Titan

FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood Blindness - No Current Treatment Exists  Stock Titan

FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood Blindness - No Current Treatment Exists - Stock Titan

Click here to get full coverage on FDA Clears Ocugen's Revolutionary Inhaled COVID-19 Vaccine for Clinical Trials - Stock Titan

FDA Clears Ocugen's Revolutionary Inhaled COVID-19 Vaccine for Clinical Trials  Stock Titan

FDA Clears Ocugen's Revolutionary Inhaled COVID-19 Vaccine for Clinical Trials - Stock Titan

Click here to get full coverage on After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner - The Business Journals

After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner  The Business Journals

After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner - The Business Journals

Click here to get full coverage on Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit  Ocugen

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen

Click here to get full coverage on Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial - Stock Titan

Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial  Stock Titan

Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial - Stock Titan

Click here to get full coverage on OCGN Earnings: Ocugen’s Q3 Results Disappoint - TipRanks

OCGN Earnings: Ocugen’s Q3 Results Disappoint  TipRanks

OCGN Earnings: Ocugen’s Q3 Results Disappoint - TipRanks

Click here to get full coverage on OCGN Latest Report - AInvest

OCGN Latest Report - AInvest

Click here to get full coverage on Ocugen Provides Business Update with First Quarter 2025 Financial Results - GlobeNewswire

Ocugen Provides Business Update with First Quarter 2025 Financial Results  GlobeNewswire

Ocugen Provides Business Update with First Quarter 2025 Financial Results - GlobeNewswire

Click here to get full coverage on Ocugen receives additional 180-day extension from Nasdaq to meet $1 minimum bid - Investing.com

Ocugen receives additional 180-day extension from Nasdaq to meet $1 minimum bid  Investing.com

Ocugen receives additional 180-day extension from Nasdaq to meet $1 minimum bid - Investing.com

Click here to get full coverage on Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial - Stock Titan

Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial  Stock Titan

Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial - Stock Titan

Click here to get full coverage on Ocugen’s Strategic Moves and Financial Projections Justify Buy Rating - TipRanks

Ocugen’s Strategic Moves and Financial Projections Justify Buy Rating  TipRanks

Ocugen’s Strategic Moves and Financial Projections Justify Buy Rating - TipRanks

Click here to get full coverage on Ocugen Secures $65M Financing, Extends Runway to 2026 as Gene Therapy Trials Advance - Stock Titan

Ocugen Secures $65M Financing, Extends Runway to 2026 as Gene Therapy Trials Advance  Stock Titan

Ocugen Secures $65M Financing, Extends Runway to 2026 as Gene Therapy Trials Advance - Stock Titan

Click here to get full coverage on Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa - Ocugen

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa  Ocugen

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa - Ocugen

Click here to get full coverage on Ocugen Provides Business Update with Third Quarter 2024 Financial Results - Yahoo Finance

Ocugen Provides Business Update with Third Quarter 2024 Financial Results  Yahoo Finance

Ocugen Provides Business Update with Third Quarter 2024 Financial Results - Yahoo Finance

Click here to get full coverage on Ocugen, Inc. (OCGN) Quarterly 10-Q Report - Quartz

Ocugen, Inc. (OCGN) Quarterly 10-Q Report  Quartz

Ocugen, Inc. (OCGN) Quarterly 10-Q Report - Quartz

Click here to get full coverage on Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - Yahoo Finance

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024  Yahoo Finance

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - Yahoo Finance

Click here to get full coverage on Ocugen stock steady as H.C. Wainwright reiterates buy rating By Investing.com - Investing.com South Africa

Ocugen stock steady as H.C. Wainwright reiterates buy rating By Investing.com  Investing.com South Africa

Ocugen stock steady as H.C. Wainwright reiterates buy rating By Investing.com - Investing.com South Africa

Click here to get full coverage on Revolutionary Eye Disease Gene Therapy Advances: Ocugen Secures Fast-Track Status in Europe - Stock Titan

Revolutionary Eye Disease Gene Therapy Advances: Ocugen Secures Fast-Track Status in Europe  Stock Titan

Revolutionary Eye Disease Gene Therapy Advances: Ocugen Secures Fast-Track Status in Europe - Stock Titan

Click here to get full coverage on IMMINENT OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

IMMINENT OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit!  ACCESS Newswire

IMMINENT OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

Click here to get full coverage on Ocugen Secures $30M Credit Facility, Extends Runway for Key Gene Therapy Trials - Stock Titan

Ocugen Secures $30M Credit Facility, Extends Runway for Key Gene Therapy Trials  Stock Titan

Ocugen Secures $30M Credit Facility, Extends Runway for Key Gene Therapy Trials - Stock Titan

Click here to get full coverage on Ocugen Advances Promising Pipeline Amid Financial Restraints - Nasdaq

Ocugen Advances Promising Pipeline Amid Financial Restraints  Nasdaq

Ocugen Advances Promising Pipeline Amid Financial Restraints - Nasdaq

Click here to get full coverage on NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation - Newswire :) Press Release Distribution

NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation  Newswire :) Press Release Distribution

NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation - Newswire :) Press Release Distribution

Click here to get full coverage on Ocugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment - TipRanks

Ocugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment  TipRanks

Ocugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment - TipRanks

Click here to get full coverage on Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 - Seeking Alpha

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3  Seeking Alpha

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 - Seeking Alpha

Click here to get full coverage on Ocugen Granted Extension to Meet Nasdaq Listing Requirements - TipRanks

Ocugen Granted Extension to Meet Nasdaq Listing Requirements  TipRanks

Ocugen Granted Extension to Meet Nasdaq Listing Requirements - TipRanks

Click here to get full coverage on Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea  GuruFocus

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus

Click here to get full coverage on Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On? - inkl

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?  inkl

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On? - inkl

Click here to get full coverage on Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa - Ocugen

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa  Ocugen

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa - Ocugen

Click here to get full coverage on State Street Corp's Strategic Acquisition of Shares in Ocugen Inc - Yahoo Finance

State Street Corp's Strategic Acquisition of Shares in Ocugen Inc  Yahoo Finance

State Street Corp's Strategic Acquisition of Shares in Ocugen Inc - Yahoo Finance

Click here to get full coverage on Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock - Ocugen

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock  Ocugen

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock - Ocugen

Click here to get full coverage on Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire

Attention Long-Term Shareholders of Driven Brands Holdings,  GlobeNewswire

Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire

Click here to get full coverage on Ocugen Provides Business Update with Third Quarter 2024 Financial Results - GlobeNewswire

Ocugen Provides Business Update with Third Quarter 2024 Financial Results  GlobeNewswire

Ocugen Provides Business Update with Third Quarter 2024 Financial Results - GlobeNewswire

Click here to get full coverage on Ocugen To Present at BIO International Convention 2025 - Yahoo Finance

Ocugen To Present at BIO International Convention 2025  Yahoo Finance

Ocugen To Present at BIO International Convention 2025 - Yahoo Finance

Click here to get full coverage on Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop - Ocugen

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop  Ocugen

Ocugen Inc (OCGN)

Price Chart

Key Statistics

Technicals

About OCGN

Latest News

Will OCGN stock go up? - AInvest

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? - Yahoo Finance

Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha

Advanced Charts

Top Gainers

Top Losers